Related Experiment Video
Updated: Jul 18, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report
1PM&R and Rheumatology Department, Medical Faculty, Akdeniz University, Antalya, Turkey. fatihcay@akdeniz.edu.tr
Abstract:
Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...